Literature DB >> 15096191

CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model.

Tai-Gyu Kim1, Chang-Hyun Kim, Eun Ha Won, Su Mi Bae, Woong-Shick Ahn, Jae-Bok Park, Jeong-Im Sin.   

Abstract

We previously reported that both E7 and CpG-oligodeoxynucleotide (ODN) are required for protecting animals from human papillomavirus (HPV) 16 E7-associated tumour challenge. Here we investigate dendritic cells (DC)-based approach in this protection. In the study, we isolated bone marrow-derived DC and stimulated DC with E7 and ODN. In vitro stimulation of DC with E7 plus ODN resulted in more production of interleukin-12, as compared to that with E7 or ODN alone. Further injection with E7+ODN-stimulated DC resulted in more significant tumour protection, as compared to stimulation with E7 or ODN alone. We further evaluated the levels of immune responses induced by DC stimulated with E7+ODN. We observed little enhancement of E7-specific antibody and T helper cell proliferative responses by E7+ODN stimulation, as compared to E7 stimulation. However, there was some enhancement of interferon-gamma (IFN-gamma) production from CD4+ T cells and a more significant production of IFN-gamma from CD8+ T cells by E7+ODN stimulation, as compared to E7 stimulation alone. This was consistent with intracellular IFN-gamma staining levels of CD8+ T cells. Tumour protection further appeared to be mediated by CD8+ T cells, as determined by in vivo T-cell depletion. Thus, these data suggest that upon ODN stimulation DC might function as a potent adjuvant for E7 protein delivery for induction of protective cellular immunity against HPV E7-associated tumour challenge.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096191      PMCID: PMC1782454          DOI: 10.1111/j.1365-2567.2004.01851.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  50 in total

1.  Suppression of immune response and protective immunity to a Japanese encephalitis virus DNA vaccine by coadministration of an IL-12-expressing plasmid.

Authors:  H W Chen; C H Pan; H W Huan; M Y Liau; J R Chiang; M H Tao
Journal:  J Immunol       Date:  2001-06-15       Impact factor: 5.422

2.  Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer.

Authors:  Alessandro D Santin; Stefania Bellone; Murat Gokden; Martin J Cannon; Groesbeck P Parham
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

3.  Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells.

Authors:  Maurizio Chiriva-Internati; Yong Liu; Emanuela Salati; Weiping Zhou; Zhiqing Wang; Fabio Grizzi; Juan J Roman; Seah H Lim; Paul L Hermonat
Journal:  Eur J Immunol       Date:  2002-01       Impact factor: 5.532

4.  Cutting Edge: CpG DNA inhibits dendritic cell apoptosis by up-regulating cellular inhibitor of apoptosis proteins through the phosphatidylinositide-3'-OH kinase pathway.

Authors:  Yunji Park; Seung Woo Lee; Young Chul Sung
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

5.  CpG oligodeoxynucleotides as vaccine adjuvants in primates.

Authors:  Daniela Verthelyi; Richard T Kenney; Robert A Seder; Albert A Gam; Brenda Friedag; Dennis M Klinman
Journal:  J Immunol       Date:  2002-02-15       Impact factor: 5.422

6.  Cytokines regulate the capacity of CD8alpha(+) and CD8alpha(-) dendritic cells to prime Th1/Th2 cells in vivo.

Authors:  R Maldonado-López; C Maliszewski; J Urbain; M Moser
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

7.  Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.

Authors:  J I Sin; J J Kim; D Zhang; D B Weiner
Journal:  Hum Gene Ther       Date:  2001-06-10       Impact factor: 5.695

8.  Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion.

Authors:  Wen-Fang Cheng; Chien-Fu Hung; Keng-Fu Hsu; Chee-Yin Chai; Liangmei He; John M Polo; Leigh A Slater; Morris Ling; T-C Wu
Journal:  Hum Gene Ther       Date:  2002-03-01       Impact factor: 5.695

9.  Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model.

Authors:  Klaus Heckelsmiller; Katharina Rall; Sebastian Beck; Angelika Schlamp; Julia Seiderer; Bernd Jahrsdörfer; Anne Krug; Simon Rothenfusser; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

10.  Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.

Authors:  Tae-Yoon Kim; Han-Jeong Myoung; Ji-Hyun Kim; In-Sung Moon; Tai-Gyu Kim; Woong-Shick Ahn; Jeong-Im Sin
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701

View more
  15 in total

1.  Mucosally delivered peptides prime strong immunity in HLA-A2.1 transgenic rabbits.

Authors:  Jiafen Hu; Nancy Cladel; Karla Balogh; Neil Christensen
Journal:  Vaccine       Date:  2010-03-21       Impact factor: 3.641

2.  DNA vaccine with α-galactosylceramide at prime phase enhances anti-tumor immunity after boosting with antigen-expressing dendritic cells.

Authors:  Daejin Kim; Chien-Fu Hung; T-C Wu; Yeong-Min Park
Journal:  Vaccine       Date:  2010-09-17       Impact factor: 3.641

Review 3.  Delivery of oligonucleotides with lipid nanoparticles.

Authors:  Yuhua Wang; Lei Miao; Andrew Satterlee; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2015-02-27       Impact factor: 15.470

4.  Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model.

Authors:  Mi Suk Kim; Jeong-Im Sin
Journal:  Immunology       Date:  2005-10       Impact factor: 7.397

5.  CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer.

Authors:  Yumin Xia; Gaurav K Gupta; Ana P Castano; Pawel Mroz; Pinar Avci; Michael R Hamblin
Journal:  J Biophotonics       Date:  2013-08-07       Impact factor: 3.207

6.  All-Atom MD Predicts Magnesium-Induced Hairpin in Chemically Perturbed RNA Analog of F10 Therapeutic.

Authors:  Ryan L Melvin; William H Gmeiner; Freddie R Salsbury
Journal:  J Phys Chem B       Date:  2017-08-10       Impact factor: 2.991

Review 7.  Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Authors:  Chien-Fu Hung; Barbara Ma; Archana Monie; Shaw-Wei Tsen; T-C Wu
Journal:  Expert Opin Biol Ther       Date:  2008-04       Impact factor: 4.388

8.  Adoptive transfer of human papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway.

Authors:  Jeong-Im Sin; Jung-Min Kim; Sung Hwa Bae; In Hee Lee; Jong Sup Park; Hun Mo Ryoo
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

9.  Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression.

Authors:  Jeong-Im Sin
Journal:  Immunology       Date:  2009-02-09       Impact factor: 7.397

10.  Targeted treatments for cervical cancer: a review.

Authors:  Oscar Peralta-Zaragoza; Víctor Hugo Bermúdez-Morales; Carlos Pérez-Plasencia; Jonathan Salazar-León; Claudia Gómez-Cerón; Vicente Madrid-Marina
Journal:  Onco Targets Ther       Date:  2012-11-02       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.